The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11150 malaria professionals are enjoying the free benefits of MalariaWorld today

vaccine

Not Open Access | Willingness to pay for a hypothetical malaria vaccine in Brazil: a cross-sectional study and the implications

January 18, 2022 - 20:45 -- NOT Open Access
Author(s): 
Labis da Costa MJ, Nascimento GC, Athie TS, Sales Silva J, Reis EA, Martin AP, Godman B, Dias Godói IP
Reference: 
J Comp Eff Res. 2022 Jan 14

Malaria is an infection caused by protozoa of genus Plasmodium, considered the one associated with increasingly large outbreaks.

RTS,S: the first malaria vaccine

January 12, 2022 - 20:03 -- Open Access
Author(s): 
Zavala F
Reference: 
J Clin Invest. 2022 Jan 4;132(1):e156588

After more than four decades of basic research and clinical trials, the World Health Organization (WHO) has recommended the malaria vaccine RTS,S for widespread use among children living in malaria endemic areas. Pioneering studies using rodent malaria models directed by Ruth S. Nussenzweig at the New York University School of Medicine demonstrated in the late 1960s that immunization with attenuated sporozoites — the infective stage of Plasmodium — induces immune responses that protect against parasite infection.

NOT Open Access | Making a good malaria vaccine better

January 5, 2022 - 20:55 -- NOT Open Access
Author(s): 
Duffy PE
Reference: 
Trends Parasitol. 2022 Jan;38(1):9-10

Last month, the World Health Organization (WHO) recommended widespread use of RTS,S/AS01 vaccine to prevent malaria in young African children, noting its 30% reduction in deadly severe malaria.

Reproducibility of malaria sporozoite challenge model in humans for evaluating efficacy of vaccines and drugs: a systematic review

December 28, 2021 - 20:55 -- Open Access
Author(s): 
Shibeshi W, Bagchus W, Yalkinoglu Ö, Tappert A, Engidawork E, Oeuvray C
Reference: 
BMC Infect Dis. 2021 Dec 20;21(1):1274

The development of novel malaria vaccines and antimalarial drugs is limited partly by emerging challenges to conduct field trials in malaria endemic areas, including unknown effects of existing immunity and a reported fall in malaria incidence. As a result, Controlled Human Malaria Infection (CHMI) has become an important approach for accelerated development of malarial vaccines and drugs. We conducted a systematic review of the literature to establish aggregate evidence on the reproducibility of a malaria sporozoite challenge model.

Seven-year kinetics of RTS, S/AS01-induced anti-CSP antibodies in young Kenyan children

December 17, 2021 - 21:26 -- Open Access
Author(s): 
Robert M. Mugo, Kennedy Mwai, Jedidah Mwacharo, Faiz M. Shee, Jennifer N. Musyoki, Juliana Wambua, Edward Otieno, Philip Bejon and Francis M. Ndungu
Reference: 
Malaria Journal 2021 20:452, 2 December 2021

RTS,S/AS01, the leading malaria vaccine has been recommended by the WHO for widespread immunization of children at risk. RTS,S/AS01-induced anti-CSP IgG antibodies are associated with the vaccine efficacy. Here, the long-term kinetics of RTS,S/AS01-induced antibodies was investigated.

Safety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccine

November 25, 2021 - 13:03 -- Open Access
Author(s): 
Webster R, Sekuloski S, McCarthy JS, et al.
Reference: 
BMC Med. 2021 Nov 22;19(1):293

There is a clear need for novel approaches to malaria vaccine development. We aimed to develop a genetically attenuated blood-stage vaccine and test its safety, infectivity, and immunogenicity in healthy volunteers. Our approach was to target the gene encoding the knob-associated histidine-rich protein (KAHRP), which is responsible for the assembly of knob structures at the infected erythrocyte surface. Knobs are required for correct display of the polymorphic adhesion ligand P. falciparum erythrocyte membrane protein 1 (PfEMP1), a key virulence determinant encoded by a repertoire of var genes.

NOT Open Access | Assessment of experimental malaria vaccine induced protection in pre-exposed populations

November 24, 2021 - 20:02 -- NOT Open Access
Author(s): 
Daubenberger C
Reference: 
Lancet Infect Dis. 2021 Nov 18:S1473-3099(21)00359-5

Efforts to control and further reduce morbidity and mortality caused by Plasmodium falciparum infections in all age groups will be substantially strengthened by development of efficacious malaria vaccines in malaria pre-exposed populations.

Insights from modelling malaria vaccines for policy decisions: the focus on RTS,S

November 23, 2021 - 09:27 -- Open Access
Author(s): 
Katya Galactionova, Thomas A. Smith and Melissa A. Penny
Reference: 
Malaria Journal 2021 20:439, 18 November 2021

Mathematical models are increasingly used to inform decisions throughout product development pathways from pre-clinical studies to country implementation of novel health interventions.

Analysis of the potential for a malaria vaccine to reduce gaps in malaria intervention coverage

November 23, 2021 - 09:25 -- Open Access
Author(s): 
H. Juliette T. Unwin, Lazaro Mwandigha, Peter Winskill, Azra C. Ghani and Alexandra B. Hogan
Reference: 
Malaria Journal 2021 20:438, 17 November 2021

The RTS,S/AS01 malaria vaccine is currently being evaluated in a cluster-randomized pilot implementation programme in three African countries. This study seeks to identify whether vaccination could reach additional children who are at risk from malaria but do not currently have access to, or use, core malaria interventions.

Pages

Subscribe to RSS - vaccine